Which has better earnings and valuation, ALT or ASRT?

Assertio has higher revenue and earnings than Altimmune. Assertio is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 14,244.93 -$88.09M -$0.93 N/A Assertio $118.71M 1.28 -$30.38M -$5.69 N/A

Is ALT or ASRT more profitable?

Assertio has a net margin of -34.94% compared to Altimmune's net margin of -214,860.98%. Assertio's return on equity of -38.72% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -42.57% -35.57% Assertio -34.94% -38.72% -13.32%

Does the media refer more to ALT or ASRT?

In the previous week, Altimmune and Altimmune both had 2 articles in the media. Altimmune's average media sentiment score of 0.71 beat Assertio's score of 0.00 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, PROK or ASRT?

Assertio has higher revenue and earnings than ProKidney. Assertio is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 526.06 -$68.99M -$0.53 N/A Assertio $118.71M 1.28 -$30.38M -$5.69 N/A

Is PROK or ASRT more profitable?

Assertio has a net margin of -34.94% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Assertio's return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -8,131.50% N/A -21.39% Assertio -34.94% -38.72% -13.32%

Does the media favor PROK or ASRT?

In the previous week, ProKidney and ProKidney both had 2 articles in the media. ProKidney's average media sentiment score of 0.62 beat Assertio's score of 0.00 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ASRT or KYTX?

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Assertio. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for Assertio. Kyverna Therapeutics' average media sentiment score of 0.52 beat Assertio's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ASRT or VECT?

Assertio presently has a consensus target price of $22.65, indicating a potential downside of 3.62%. Given Assertio's stronger consensus rating and higher probable upside, analysts clearly believe Assertio is more favorable than VectivBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ASRT or VECT?

VectivBio has lower revenue, but higher earnings than Assertio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assertio $118.71M 1.28 -$30.38M -$5.69 N/A VectivBio N/A N/A N/A N/A N/A

Is ASRT or VECT more profitable?

VectivBio has a net margin of 0.00% compared to Assertio's net margin of -34.94%. VectivBio's return on equity of 0.00% beat Assertio's return on equity. Company Net Margins Return on Equity Return on Assets Assertio -34.94% -38.72% -13.32% VectivBio N/A N/A N/A

Does the media prefer ASRT or VECT?

In the previous week, Assertio had 1 more articles in the media than VectivBio. MarketBeat recorded 2 mentions for Assertio and 1 mentions for VectivBio. Assertio's average media sentiment score of 0.00 equaled VectivBio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VectivBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ASRT or CTNM?

In the previous week, Assertio and Assertio both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 0.96 beat Assertio's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Assertio (ASRT) Competitors

$23.50 0.00 (0.00%)

As of 06/17/2026

Compare

ASRT vs. ALT, PROK, KYTX, VECT, and CTNM

Should you buy Assertio stock or one of its competitors? MarketBeat compares Assertio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assertio include Altimmune (ALT), ProKidney (PROK), Kyverna Therapeutics (KYTX), VectivBio (VECT), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Assertio compare to Altimmune?

Altimmune (NASDAQ:ALT) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Assertio has a net margin of -34.94% compared to Altimmune's net margin of -214,860.98%. Assertio's return on equity of -38.72% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Assertio	-34.94%	-38.72%	-13.32%

Assertio has higher revenue and earnings than Altimmune. Assertio is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,244.93	-$88.09M	-$0.93	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

Altimmune presently has a consensus price target of $15.71, indicating a potential upside of 436.32%. Assertio has a consensus price target of $22.65, indicating a potential downside of 3.62%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 5.7% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Altimmune and Altimmune both had 2 articles in the media. Altimmune's average media sentiment score of 0.71 beat Assertio's score of 0.00 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Altimmune has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Summary

Altimmune beats Assertio on 8 of the 15 factors compared between the two stocks.

How does Assertio compare to ProKidney?

ProKidney (NASDAQ:PROK) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

ProKidney has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Assertio has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Assertio has higher revenue and earnings than ProKidney. Assertio is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	526.06	-$68.99M	-$0.53	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

51.6% of ProKidney shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 5.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Assertio has a net margin of -34.94% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Assertio	-34.94%	-38.72%	-13.32%

ProKidney presently has a consensus price target of $12.00, suggesting a potential upside of 674.19%. Assertio has a consensus price target of $22.65, suggesting a potential downside of 3.62%. Given ProKidney's stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, ProKidney and ProKidney both had 2 articles in the media. ProKidney's average media sentiment score of 0.62 beat Assertio's score of 0.00 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Assertio on 12 of the 16 factors compared between the two stocks.

How does Assertio compare to Kyverna Therapeutics?

Assertio (NASDAQ:ASRT) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Kyverna Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

49.0% of Assertio shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Assertio presently has a consensus target price of $22.65, suggesting a potential downside of 3.62%. Kyverna Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 277.83%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

Assertio has higher revenue and earnings than Kyverna Therapeutics. Assertio is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Assertio. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for Assertio. Kyverna Therapeutics' average media sentiment score of 0.52 beat Assertio's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kyverna Therapeutics beats Assertio on 10 of the 15 factors compared between the two stocks.

How does Assertio compare to VectivBio?

Assertio (NASDAQ:ASRT) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

49.0% of Assertio shares are owned by institutional investors. 5.7% of Assertio shares are owned by insiders. Comparatively, 9.7% of VectivBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

VectivBio has a net margin of 0.00% compared to Assertio's net margin of -34.94%. VectivBio's return on equity of 0.00% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
VectivBio	N/A	N/A	N/A

VectivBio has lower revenue, but higher earnings than Assertio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
VectivBio	N/A	N/A	N/A	N/A	N/A

Assertio presently has a consensus target price of $22.65, indicating a potential downside of 3.62%. Given Assertio's stronger consensus rating and higher probable upside, analysts clearly believe Assertio is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Assertio had 1 more articles in the media than VectivBio. MarketBeat recorded 2 mentions for Assertio and 1 mentions for VectivBio. Assertio's average media sentiment score of 0.00 equaled VectivBio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VectivBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Assertio beats VectivBio on 5 of the 9 factors compared between the two stocks.

How does Assertio compare to Contineum Therapeutics?

Assertio (NASDAQ:ASRT) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Assertio and Assertio both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 0.96 beat Assertio's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio presently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 37.27%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Assertio has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Assertio has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Contineum Therapeutics	$50M	10.90	-$59.98M	-$1.95	N/A

49.0% of Assertio shares are owned by institutional investors. 5.7% of Assertio shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Contineum Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Contineum Therapeutics' return on equity of -27.09% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Summary

Contineum Therapeutics beats Assertio on 10 of the 15 factors compared between the two stocks.

Get Assertio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASRT vs. The Competition

Export

Metric	Assertio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$151.81M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	-4.13	18.77	26.96	24.38
Price / Sales	1.28	344.35	521.19	91.92
Price / Cash	1,437.29	56.83	48.59	59.36
Price / Book	1.61	4.20	10.95	6.33
Net Income	-$30.38M	$65.13M	$3.59B	$331.02M
7 Day Performance	N/A	-2.63%	-1.49%	-0.33%
1 Month Performance	N/A	2.14%	2.75%	-1.29%
1 Year Performance	137.27%	23.26%	28.51%	21.30%

Assertio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASRT Assertio	1.5467 of 5 stars	$23.50 flat	$22.65 -3.6%	N/A	$151.81M	$118.71M	N/A	20	News Coverage
ALT Altimmune	2.3079 of 5 stars	$3.05 -1.1%	$15.71 +416.1%	-31.2%	$588.27M	$40K	N/A	50	Positive News Gap Up
PROK ProKidney	1.6443 of 5 stars	$1.92 -3.8%	$9.00 +370.0%	-58.0%	$578.45M	$889K	N/A	3	News Coverage
KYTX Kyverna Therapeutics	2.6507 of 5 stars	$9.53 +4.0%	$30.00 +214.8%	+80.9%	$573.74M	N/A	N/A	96
VECT VectivBio	N/A	$16.85 flat	N/A	N/A	$573.24M	$27.34M	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASRT) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assertio (ASRT) Competitors